Clinical trial results: A RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLIND, INTERVENTIONAL, MULTICENTER, PHASE I/IIA CLINICAL TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF ALLO-APZ2-PAOD FOR THE TREATMENT OF PERIPHERAL ARTERIAL OCCLUSIVE DISEASE (PAOD)

Summary

| Results information | |
|------------------------------|--|
| | |
| | |
| | |
| Trial information | |
| Trial identification | |
| | |
| Additional study identifiers | |
| | |
| | |

Sponsors

| • | | |
|---|--|--|
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

| Paediatric regulatory details | | |
|-------------------------------|--|--|
| | | |
| | | |
| | | |

| Results analysis stage | | |
|------------------------|--|--|
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

General information about the trial

| Population of trial subjects | | |
|-------------------------------|--|--|
| Subjects enrolled per country | | |
| | | |
| | | |
| | | |
| | | |
| | | |

| Subjects enrolled per age group | |
|---------------------------------|--|
| | |
| | |

Recruitment

Pre-assignment

Period 1

| Arm title | |
|-----------|--|
| | |

| Number of subjects in period 1 ^[1] | |
|--|--|
| | |
| | |
| | |

| Period 2 | | |
|-----------|--|--|
| | | |
| | | |
| | | |
| | | |
| | | |
| Arms | | |
| | | |
| Arm title | | |
| | | |

| Arm title | |
|-----------|--|
| | |

| Reporting groups | | |
|------------------|--|--|
| | | |
| | | |
| | | |
| | | |
| | | |

| Reporting group values | | |
|------------------------|--|--|
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

| End | points |
|------|--------|
| LIIG | points |

| · · | sitting groups | |
|----------------|--------------------|---------------------------------------|
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | 1 |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| Primary: Perce | nt change in total | l wound size from Baseline at Week 12 |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | 1 |
| | | |

| End point values | | |
|------------------|--|--|
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

Statistical analyses

| Statistical analysis title | |
|----------------------------|--|
| Statistical analysis title | |

Adverse events information

| Dictionary used | |
|------------------|--|
| | |
| | |
| Reporting groups | |
| | |
| | |
| | |

| Serious adverse events | | |
|------------------------|------|--|
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

More information

Substantial protocol amendments (globally)

| Date | Amendment |
|------|-----------|
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

Interruptions (globally)

| Date | Interruption | Restart date |
|------|--------------|--------------|
| | | |
| | | |
| | | |

Limitations and caveats